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PETAbstract Assessment of the response to treatment of metastases is crucial in daily oncological
practice and clinical trials. For soft tissue metastases, this is done using computed tomography
(CT), Magnetic Resonance Imaging (MRI) or Positron Emission Tomography (PET) using
validated response evaluation criteria. Bone metastases, which frequently represent the only
site of metastases, are an exception in response assessment systems, because of the nature
of the ﬁxed bony defects, their complexity, which ranges from sclerotic to osteolytic and
because of the lack of sensitivity, speciﬁcity and spatial resolution of the previously available
bone imaging methods, mainly bone scintigraphy. Techniques such as MRI and PET are able
to detect the early inﬁltration of the bone marrow by cancer, and to quantify this inﬁltration
using morphologic images, quantitative parameters and functional approaches. This paper
highlights the most recent developments of MRI and PET, showing how they enable early
detection of bone lesions and monitoring of their response. It reviews current knowledge, puts
the different techniques into perspective, in terms of indications, strengths, weaknesses andelgium.
2520 F.E. Lecouvet et al. / European Journal of Cancer 50 (2014) 2519–2531complementarity, and ﬁnally proposes recommendations for the choice of the most adequate
imaging technique.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Evaluation of response to therapy is a pivotal compo-
nent of cancer imaging. For the last 20 years, Response
Evaluation Criteria in Solid Tumours (RECIST) criteria
have been used for soft tissue metastases, but bone
lesions remain ‘non-measurable’ [1,2]. Therefore, in can-
cers such as prostate and breast where metastases occur
preferentially or exclusively in the bone, response assess-
ment is diﬃcult. Serum biomarkers where available (e.g.
Prostate Speciﬁc Antigen (PSA) in prostate cancer) pro-
vide a means for monitoring treatment response; bone
resorption biomarkers such as n-telopeptide (NTX) have
also been explored [3]. However, serum biomarkers do
not address heterogeneity of response at diﬀerent sites
as resistant clones emerge. Advances in Magnetic Reso-
nance Imaging (MRI) and Positron Emission Tomogra-
phy (PET), along with their increased availability, have
led to their use for response assessment of bony metasta-
ses. Evaluation of bone metastasis response and the
development of criteria of bone response are current pri-
orities in the EORTC Imaging group, because they are
required for several ongoing multicentre studies. This
paper therefore discusses current state-of-the-art MRI
and nuclear medicine imaging approaches for detecting
and evaluating response in bone metastases.2. Methods of detecting bone metastases
2.1. Magnetic Resonance Imaging (MRI)
Morphological approaches use measurements of
tumour number and size, paralleling measurements for
‘soft tissue’ metastases. Functional techniques (Dynamic
contrast-enhanced (DCE)-MRI and diﬀusion-weighted
(DW)-MRI) widely studied in soft tissue disease [4–6],
provide assessments of response that predate volume
changes [7,8] but have only recently been extended to
the study of bone metastases [9–13].2.1.1. Morphologic MRI
Morphologic MRI is superior to radiographs, com-
puted tomography (CT) and bone scintigraphy (BS)
because it detects the early replacement of marrow fat
and haematopoietic cells by tumour, prior to trabecular
changes. T1 changes are independent of associated scle-
rosis and are applicable across tumour types [14]. On
T1-weighted (T1-W) images, high contrast between
lesions and normal marrow enables derivation of an
index of tumour load [12]. T2-weighted (T2-W) and shorttau inversion recovery (STIR) images reﬂect lesion com-
position (water content, ﬁbrosis and sclerosis) rather
than marrow replacement, and show variable signal
[15]. Although whole body coverage is feasible, limiting
coverage to the axial skeleton where metastases predom-
inate minimises examination time to 20 min [16] and out-
performs BS [17] (Fig. 1). A T2* measurement may be
used to quantify bone sclerosis and has shown changes
in bone density that parallel those found on CT [18].2.1.2. Diﬀusion-weighted MRI (DW-MRI)
DW-MRI is sensitive to thermal motion (diﬀusion) of
water molecules. In biologic tissues barriers such as endo-
thelium, cell membranes, components of the extracellular
matrix and intracellular organelles restrict diﬀusion;
increase or decrease in these barriers modiﬁes the degree
of water diﬀusion leading to a reduction or retention of
MR signal. Tumour foci are visualised as increased sig-
nal-intensity on DW-MRI images with a corresponding
decrease in the measured Apparent Diﬀusion Coeﬃcient
(ADC), which represents the rate of signal loss with
increasing diﬀusion weighting [19]. As the diﬀusion prop-
erties of bone metastases are signiﬁcantly diﬀerent to age-
matched normal marrow [20], DW-sequences are now
almost routinely used as an adjunct to conventional T1-
W images [15]. However, DW-MRI lacks speciﬁcity,
emphasising the need for morphologic sequences [21,22].2.1.3. Perfusion MRI (DCE-MRI)
DCE-MRI requires injection of a paramagnetic con-
trast agent which shortens T1 relaxation of tissue water.
The mass transport of this agent through the vascular,
extravascular and extracellular spaces and the diﬀer-
ences in water and contrast compartmentalisation in
the tissues [6] are used to model the vascular and inter-
stitial properties of tissues. The most frequently reported
parameter Ktrans is constructed from a lumped represen-
tation of perfusion and permeability and has been vali-
dated as an imaging biomarker of tumour vasculature
(angiogenesis) and of the early eﬀects of treatment on
vascularisation [6,23]. DCE-MRI has no role in the
detection and global quantiﬁcation of bone metastatic
disease, as anatomic coverage is limited, and standardi-
sation of acquisition techniques across diﬀerent
platforms and centres is challenging.2.2. Nuclear medicine
Techniques reﬂect the functional/biologic properties
of tissues and are based on two diﬀerent physical
Fig. 1. Superiority of morphologic Magnetic Resonance Imaging
(MRI) over bone scintigraphy for lesion detection and response
assessment in a patient with prostate cancer metastatic to bone. (a)
Initial sagittal T1-weighted MR image of the lumbar spine shows focus
of low signal intensity within L3 corresponding to metastasis (arrow).
(b) The concurrent bone scintigraphy does not show any evident
abnormal uptake. (c) After a 3-month systemic therapy, follow-up MR
image shows complete disappearance of the lesion. (d) The corre-
sponding bone scintigraphy does not show a signiﬁcant change.
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scintigraphy/single photon emission computed tomogra-
phy (SPECT or tomoscintigraphy) and PET. Both
modalities require administration of a radiopharmaceu-
tical and are associated with anatomic imaging in hybrid
systems: SPECT/CT, PET/CT and PET/MRI [23].
Compared to SPECT, PET has a superior image resolu-
tion and enables quantiﬁcation of the uptake of target
lesions. The standardised uptake value (SUV), quantiﬁes
the intensity of the signal in a region-of-interest. SUVmax
is the value limited to the most active pixel and is repro-
ducible across observers because it is minimally depen-
dent on the region-of-interest deﬁned. SUVmax in
malignant lesions is higher than in benign ones aiding
their diﬀerentiation.
Radioactive tracers for bone are distinguished accord-
ing to the underlying functional/biologic mechanism.
Tracers of the osseous matrix (99mTc-bisphospho-
nates for BS and SPECT, and 18F-ﬂuoride for PET)
image the secondary biologic reaction of the host bone
to the tumour; they are sensitive but not speciﬁc and
are unable to detect bone marrow involvement.
Cancer-oriented tracers are either non-speciﬁc
(18F-ﬂuorodeoxyglucose (FDG), 11C-choline or
18F-ﬂuorocholine (FCH), 18F-ﬂuoroDOPA (FDOPA))
or cancer-speciﬁc (111In-pentetreotide and 123I-metaiod-
obenzylguanidine (MIBG) for SPECT, 124I or somato-
statin analogues labelled with 68Ga for PET); ligands
of oestrogen [24–26], testosterone [27] and gastrin releas-
ing peptide receptor [28], or prostate-speciﬁc membrane
antigen (PSMA)) [29] remain research tools.2.2.1. Tracers of the osseous matrix
Availability and low cost mean that BS and SPECT
using 99mTc-bisphophonates are widely used. Targeted
X-rays are frequently required to distinguish malignant
from benign causes of scintigraphic uptake. The addition
of SPECT and SPECT/CT to BS has detected more foci
and reduced the number of equivocal foci [30–33] but sen-
sitivity remains lower than with morphological MRI
[17,34]. One study (n = 40) rated 61% of lesions equivocal
on BS and SPECT versus 8% on SPECT/CT [35]. In
another series (n = 42), SPECT/CT reduced the propor-
tion of patients with equivocal ﬁndings from 48% to
14% and proportion of equivocal lesions from 31% to
9% [30]. Improvements are mostly observed for lytic
lesions [34]. The accuracy of 18F-ﬂuoride bone PET has
been demonstrated in numerous studies, and a better sen-
sitivity compared to BS [32] and SPECT [36–38]
documented.2.2.2. Cancer-oriented tracers
18F-FDG, a glucose analogue PET radiotracer, com-
monly used for imaging solid cancers [39] is superior to
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tration in haematologic malignancies [41], as well as
for detecting lytic or mixed osteolytic-osteoblastic
metastases in cortical bone. Discrepancies in early stud-
ies comparing 18F-FDG-PET and BS were related to
the proportion of osteoblastic metastases not readily
detected by 18F-FDG [32]. 18F-FDG-PET/CT is also
superior to 18F-ﬂuoride-PET/CT for detecting bone
metastases from head and neck cancers [42], but slightly
inferior when the primary was lung or breast cancer
[43,44]. This lack of sensitivity of 18F-FDG-PET to
detect osteoblastic bone metastases can be compensated
by using the CT component of PET/CT, read in bone
window mode, which was not done in earlier studies.
In prostate cancer, 11C-choline and 18F-FCH deliver
similar results to 18F-FDG in other cancers. Similar lim-
itations of sensitivity in osteoblastic lesions and of spec-
iﬁcity in infectious or inﬂammatory lesions apply.
Performance is similar to 18F-ﬂuoride-PET, with better
speciﬁcity and detection of soft tissue lesions [45]. Spe-
ciﬁc tracers can be used for particular tumour types:
124I for diﬀerentiated thyroid cancer [32] and 18F-ﬂuoro-
estradiol (FES) for breast cancer. The latter detected 341
bone lesions, compared with 246 by conventional
imaging in 33 patients [26]. 18F-FDOPA is advocated
for medullary thyroid cancer, pheochromocytoma, para-
ganglioma and midgut tumours, and somatostatin recep-
tor PET (with 68Ga-DOTATOC) has been trialled in
other types of neuroendocrine tumours [46]. Similarity
in chemical structure between tracers and therapeutic
agents may also be considered to anticipate the likeli-
hood of success of tumour targeting drugs (e.g. oestrogen
receptor imaging prior to anti-oestrogen therapy) [25].3. Monitoring treatment response
3.1. Magnetic Resonance Imaging
Numerous studies have demonstrated the value of
MRI for monitoring response of bone metastases to
treatment. These are largely single-centre trials with lim-
ited patient numbers in a variety of tumours, demon-
strating heterogeneity of response, variation in its
onset and duration and inconsistent correlation of imag-
ing ﬁndings with progression-free survival (PFS) and
overall survival (OS). Multicentre studies are now
standardising technical factors and post-processing
methods, and evaluating the reproducibility of
measurements.3.1.1. Morphologic MRI
Simplicity of implementation is appealing for multi-
centre studies. Use of T1-W spine and pelvis MRI in
breast and prostate cancer [12,47] followed evidence that
T1-W MRI detected more bone metastases than BS [48];
however in breast cancer patients T1-W MRI correctlypredicted disease progression in 79% but did not identify
response [49]. Tumour volumetry (with response deﬁned
by pain score/analgesia requirement, [CA15-3], BS and
plain radiographs) showed concordance with response
in 61% of cases [50]. Fat-saturated sequences improve
identiﬁcation of partial response because of the recogni-
tion of the return of marrow fat in responding lesions
[51]. In patients with castrate resistant prostate cancer,
(measurable lesions deﬁned by largest maximal diame-
ter > 2 slice thickness), T1-W MRI more than doubled
the proportion of patients with measurable lesions (soft-
tissue lesions on CT 29%, skeletal lesions on MRI 66%)
and enabled distinction of partial and complete
response, stable disease and progression [52] (Fig. 1).
Thus MRI size/volume measurements are useful for
response assessment over and above BS, which only
identiﬁes progression.3.1.2. Functional MRI
Preclinical studies have provided critical insight into
DW-MRI changes with treatment [53]. In a mouse
model of prostate cancer treated with docetaxel,
increased diﬀusion on functional diﬀusion maps (fDM)
after treatment corresponded to local loss of cell viabil-
ity at histology treatment. Lee [54] and Rozel [55]
reported a signiﬁcant increase in ADC values over time
in responders; however, in a rat model of bone metasta-
ses from breast cancer (cells MDA-MB-231), ADC was
not signiﬁcantly aﬀected in treated rats compared to
controls despite signiﬁcant changes in DCE-MRI
parameters [56].
In the clinic, an early study in 26 patients indicated
that mean ADC in the majority of lesions from both
responders and progressors showed a signiﬁcant increase
at 12 weeks, although some lesions in both groups dem-
onstrated a fall in ADC greater than the limits of repro-
ducibility of the technique [20]. This study concluded
that the heterogeneity of changes in ADC is likely related
to the composition of bone marrow resulting in opposing
eﬀects on ADC (Fig 2). A smaller study investigating the
response to anti-androgen treatment of bone metastases
in prostate cancer using fDM observed a parallelism
between decrease in PSA and increase in ADC in bone
metastases, but conﬁrmed the heterogeneity of ﬁndings
[57]. Recent larger studies demonstrated the value of
whole body DW-MRI techniques [58,59]. A pilot study
(n = 10) of DCE-MRI parameters also demonstrated
potential for early response assessment [60].3.1.3. Multiparametric MRI
Histologically, bone metastases in animal models are
hypercellular, solid masses with well-circumscribed mar-
gins [61]. On T1- and T2-W images they are classically
low in signal-intensity, but higher in signal-intensity
than adjacent muscle [61]. Their vascularity makes them
highly permeable and dense cellularity causes restricted
Fig. 2. Whole-body diﬀusion weighted images in a woman with
metastatic breast cancer before (a) and 4 weeks after (b) treatment with
cytotoxic chemotherapy. (a) A threshold value of the signal intensity
on high b-value (b = 900 s/mm) images has been used to segment out
focal areas of diﬀusion restriction within the bone marrow that
represent metastatic lesions. (b) After treatment, a reduction in the size
and number of lesions is indicative of response (courtesy D. Collins and
M. Blackledge).
Fig. 3. Bone scintigraphy (BS) shows metastatic bone disease progression de
uptake in the lower thoracic and lumbo-sacral spine. (b) One-year examin
examination conﬁrms progression, ruling out a benign ﬂare phenomenon.
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return of marrow fat, ﬁbrosis and sclerosis, all with
opposing eﬀects on multiparametric MR images. Fat
and water distribution (spin echo), indirect visualisation
of bone trabeculae (in-phase gradient echo), evaluation
of bone oedema and cell density (diﬀusion) and vascu-
larisation (contrast medium uptake) can be combined
for response assessment. Vassiliou et al. [62] proposed
a response measure using a normalised parameter
change. However, while the sensitivity of MRI is high,
speciﬁcity requires improvement; a good technical
understanding and an informed choice of acquisition
sequences can achieve this.
Analytical methods to interrogate intra-lesional het-
erogeneity of signal-intensity and separate the compo-
nents of response assessment are essential. The use of
fDM has been explored in bony metastatic prostate can-
cer [63]. Pixel-by-pixel histogram plots, and changes in
histogram metrics (centile values, skewness and kurto-
sis) have been investigated as response indicators [39].
The identiﬁcation of threshold values of ADC to deﬁne
fat fraction versus cellular marrow helps in distinguish-
ing responders from progressors [59,64].
A confounding factor in interpretation is the concom-
itant use of bisphosphonates [65,66] to reduce skeletalspite chemotherapy. (a) Baseline BS reveals several foci of radionuclide
ation shows increased uptake in these foci and new foci. (c) Two-year
2524 F.E. Lecouvet et al. / European Journal of Cancer 50 (2014) 2519–2531morbidity (pain, fracture) and normalise bone resorp-
tion. Their isolated eﬀects on functional MRI parame-
ters have not to date been reported.3.2. Nuclear medicine
3.2.1. Tracers of the osseous matrix
Whole-body BS visually estimates therapeutic
response by evaluating number and intensity of hot
spots (Fig. 3). Speciﬁcity of the examination is weak
and predictive value low. Improvements in accuracy
by quantitative estimation of uptake have been
attempted: a computer-assisted Bone Scan Index (BSI)
[67] determined after 16 weeks of chemotherapy in
patients with castrate-resistant prostate cancer has been
shown to correlate with OS. Another commercially
available automated system uses a ‘Bone Scan Lesion
Area’ [68].
SPECT/CT for treatment monitoring is limited by
hardware which prevents a whole-body acquisition in
a reasonable time frame (so risking missing lesions if
coverage is conﬁned to a region e.g. spine, pelvis), lack
of quantiﬁcation for longitudinal follow-up and the ﬂare
reaction (ﬁrst described in the 1980s [69–72]) where mis-
interpretation of new foci or increased intensity of exist-
ing lesions as a result of remineralisation of bone
metastases occurs [73,74]. Persistent uptake within a
responding metastasis or interaction of bisphosphonate
therapy add further complexity [75,76]. Solutions to
avoid misinterpretation of the ﬂare reaction are to wait
a longer time before evaluating response (6 months by
MD Anderson criteria), or repeating the BS.
Bone PET can also be used for treatment monitoring
[77], although the ﬂare reaction may occur [78].
Although the therapeutic regimen of bisphosphonates
decreases 18F-ﬂuoride uptake, the image readability
seems unaﬀected by this treatment, in contrast with
the disputed interference of bisphosphonates on read-
ability of BS [79]. Haematopoietic growth factors used
in association with cytotoxic chemotherapy may result
in false positive uptake on 18F-FDG PET or 18F-FCH,
but this interference has not been reported with
18F-ﬂuoride PET encouraging its use in patients whose
treatment regimens incorporate such agents [80,81].ig. 4. FDG PET/CT performed at baseline and after 2 months of
ormone therapy by letrozole in a patient with invasive ductal cancer
rade II, ER+, PR+, Her2–, Ki67 15%). (a) Sagittal PET/CT at
aseline shows two vertebral foci in T10 and L2 (top). These foci are
o longer visible on the study performed after 2 months of hormone
erapy (bottom). (b) Semi quantitative analysis of the response of the
10 lesion. The SUVmax decreases from 5.5 at baseline (top) to 2.6
53%) after two months of treatment (bottom), conﬁrming the
etabolic response, whereas CT shows no signiﬁcant change. (c)
etastatic invasion of the proximal left humerus visible at baseline
op) shows no evident reduction in size after two months of treatment
ottom), but FDG uptake appears less intense. The baseline SUVmax
ecreases from 4 to 2.9 (–28%) after treatment, indicating partial
metabolic response.3.2.2. Cancer-oriented tracers
As with soft-tissues, the role of 18F-FDG-PET or
PET/CT for response assessment has been documented
(Fig. 4). In breast cancer [82], quantiﬁcation has proven
superior to visual evaluation although visual interpreta-
tion of response after three courses predicted survival in
47 breast cancer patients (27 with bone and visceral
metastases) [83]. Quantiﬁcation is necessary for charac-
terising partial metabolic response (PMR) or stable met-
abolic disease (SMD). The EORTC [84] and PET
response criteria in solid tumours (PERCIST) [85] crite-F
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Table 1
Criteria for assessing response on Positron Emission Tomography (PET) studies.
European Organisation for Research and
Treatment of Cancer criteria
(EORTC criteria)
PET response criteria in solid tumors (PERCIST criteria)
Complete metabolic
response (CMR)
Resolution of the tumour uptake Resolution of the uptake of all tumour foci which cannot be distinguished
from background. No new focus
Partial metabolic
response (PMR)
>15% reduction in SUVmax after 1 cycle;
>25% reduction after >1 cycle
Reduction in SULpeak of 30% (reduction of 0.8 in absolute value)
Stable metabolic
disease (SMD)
15% decrease to 20% increase in SUVmax 30% decrease to 30% increase in SULpeak(increase of <0.8 in absolute
value)
Progressive
metabolic disease
(PMD)
>20% increase in SUVmax or appearance of
new metabolic foci
>30% increase in SULpeak or visible increase in extent of tracer tumour
uptake or new tracer-avid lesions that are typical of cancer and not
related to treatment eﬀect or infection
Note: SULpeak is SUV of a 1–2 cm region of interest (ROI) in tumour. normalised with lean body mass.
F.E. Lecouvet et al. / European Journal of Cancer 50 (2014) 2519–2531 2525ria for quantifying response (Table 1) yield very similar
response classiﬁcations of patients [86,87].
Sequential 18F-FDG-PET/CT studies in breast can-
cer [88] reported a correlation between the PET ﬁndings
and the tumour marker level; increasing 18F-FDG
uptake on PET and lytic changes on CT indicated dis-
ease progression. A heterogeneous metabolic response
in a study of 25 bone-dominant metastatic breast cancer
patients [89] showed discordant responses between osse-
ous and extra-osseous metastases in 30% and a lower
time to progression in those with homogeneous non-
response. 18F-FDG can present early ‘metabolic ﬂare’:
a 28% mean increase in 18F-FDG uptake was observedFig. 5. Response evaluation with 18F-ﬂuorocholine PET/CT in a
patient with castration resistant prostate cancer (maximum intensity
pixel (MIP) whole body volume rendering). (a) At baseline, numerous
foci corresponding to pelvic lymph nodes and to multiple bone lesions
are visible. (b) After six cycles of docetaxel chemotherapy, metastatic
lymph nodes are no longer visible and the bone lesion uptake decreases
signiﬁcantly. Concurrently, the serum level of PSA decreases from
1520 to 230 ng/mL (–85%).7–10 days after initiation of tamoxifen in 20 of 21 bony
metastatic breast cancer responders [90]. However,
reduction in 18F-FDG-PET/CT uptake after hormonal
treatment in 22 patients with metastatic breast cancer
(bone metastases in 68% of cases) predicted PFS but
not OS at 27 months [91].
11C-choline or 18F-FCH also promise potential as
early response biomarkers in prostate metastases [92]
(Fig. 5). 18F-FDOPA is currently the best PET tracer
for detecting medullary thyroid carcinoma, but response
assessment data are not available. 68Ga-DOTATOC has
been used for response assessment in other neuroendo-
crine tumours but showed no advantage over conven-
tional anatomic imaging [93], although it detected new
metastases earlier during therapy. To image neuroblas-
toma, pheochromocytoma and paraganglioma
123I-MIBG is considered the reference SPECT tracer
but it can be disappointing in the detection of bone
lesions [94–96], as can 111In-pentetreotide, the reference
SPECT tracer for digestive neuroendocrine tumours
[97–99]. Thus, the evidence for the use of cancer-speciﬁc
tracers for monitoring bone metastases, remains for the
moment with 18F-FDG [100], except in prostate cancer.
The integrin av b3 receptor is upregulated on tumour
cells and endothelium and plays important roles in angi-
ogenesis and metastatic spread, particularly to bone.
Increased uptake of a peptide with a high aﬃnity for
these integrins was demonstrated on PET in primary
breast cancer and its metastases in bone or soft tissue
[101]. It could be a companion diagnostic to indicate
and monitor anti-angiogenic therapy.
4. Practical recommendations when considering an
imaging pathway
In prostate cancer, disease progression on BS (new
lesions), currently remain the only FDA recognised cri-
teria for bone lesion response evaluation [102]. The
availability of new imaging biomarkers derived from
MRI and PET is changing this [103–106] but the choice
Fig. 6. Flow chart of recommended imaging pathway in evaluating bony metastatic disease. Dotted arrow indicates technique poorly indicative of
response. Tc = Technetium; BP = bisphosphonate; ASMRI =MRI limited to the axial skeleton (spine, pelvis and proximal femurs; WB-
MRI =Magnetic Resonance Imaging (MRI) of the whole body; FDG = 18F-ﬂuoro-deoxy-glucose; NaF = sodium 18F-ﬂuoride; CH = choline;
Prog = Progressive disease; SD = stable disease; PR = partial response; CR = complete response.
Table 2
Proposed speciﬁc recommendations for assessing bone metastases, according to primary cancer and risk of bone involvement.
Primary cancer First choice (clinical trials, high risk) Second choice (routine, Magnetic Resonance Imaging (MRI) or
Positron Emission Tomography (PET) not easily available)
Prostate Axial skeleton MRI (AS-MRI),
whole-body MRI (WB-MRI)
11C or 18F-choline PET/computed
tomography (CT)
Bone scintigraphy ± targeted X-rays
Breast AS-MRI, WB-MRI
18F-ﬂuorodeoxyglucose (FDG) PET;
18F-ﬂuoride PET, 18F-ﬂuoroestradiol (FES)
Bone scintigraphy ± targeted X-rays
Thyroid WB-MRI
124I PET (diﬀerentiated)
18F-FDG-PET (iodine-negative)
18F-ﬂuoroDOPA (FDOPA) (medullary)
131I scintigraphy/SPECT (diﬀerentiated)
Neuroendocrine WB-MRI
68Ga-somatostatine analogue PET (e.g.
DOTATOC)
18F-FDOPA PET (midgut,
phaeochromocytoma, paraganglioma,
neuroblastoma)
18F-FDG PET(aggressive forms)
111In-pentetreotide SPECT
123I-metaiodobenzylguanidine (MIBG) SPECT
Other malignancies (H&N,
kidney, pancreas, testis . . .)
WB-MRI
18F-FDG PET; 18F-ﬂuoride PET
11C or 18F-choline PET/CT (hepatocellular
carcinoma)
Bone scintigraphy ± targeted X-rays
2526 F.E. Lecouvet et al. / European Journal of Cancer 50 (2014) 2519–2531of biomarker can remain confusing. In making that
choice, the primary tumour type (Fig. 6), the metastatic
phenotype and the availability and cost of the imaging
techniques are important.
MRI overwhelmingly oﬀers a ‘one size ﬁts all’
solution regardless of tumour phenotype (ie, scle-rotic/lytic/diﬀuse) or metabolism, and is not prone
to ﬂare response. However, where bone accounts for
only a minority of secondary lesions, priority should
be given to the most eﬀective technique for visualising
the most frequently involved organs; 18F-FDG-PET/
CT will often be that technique. In speciﬁc tumour types,
Table 3
Merits and limits of available imaging modalities for evaluation of response of bone metastases with key references quoted (Legend: – = none,
+ = low, ++ = fair, +++ = high).
T1-weighted
(T1-W)
Magnetic
Resonance
Imaging (MRI)
Diﬀusion-
weighted
(DW)-MRI
Dynamic
contrast-
enhanced
(DCE)-MRI
Bone
scintigraphy
18F-ﬂuoride
Positron
Emission
Tomography
(PET)/computed
tomography (CT)
18F-ﬂuorodeoxyglucose
(FDG) PET/CT
18F-choline
PET/CT
Eﬀect measured Marrow
replacement
Cellularity Vascularity Bone turnover Bone turnover Glucose
metabolism
Cell turnover
Availability ++ + + +++ + ++ +
Whole body coverage +++ +++ + +++ +++ +++ +++
Reproducibility [20,45] +++ ++ + +++ +++ +++ +++
Ease of use in
multicentre trials [57,60]
+++ + + +++ + +++ +
Aﬀordability +++ ++ ++ +++ ++ ++ ++
Duration: tracer
uptake/imaging
–/15–30 min
(axial skeleton-
whole body)
–/20 min –/3 min 2–3 h/20–45 min
(planar-torso
SPECT-CT)
1 h/20–30 min 45 min/
20–30 min
–/20–30 min
Radiation free Yes Yes Yes No No No No
True response
categorisation
Yes Yes ? No (progr./no
progr.)
? Yes Yes
Proven relation
to PFS/OS
– – – +++ – +++ –
Published
multicentre studies
++ – – +++ + +++ +
Applicability to all
tumour types
+++ +++ +++ + ++ ++ +
Established response
criteria [12,39,84,85]
+++ ++ – + + +++ +
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receptor ligand) may replace or complement 18F-FDG.
BS and SPECT are useful in osteosclerotic metastases
but are not indicated in lytic disease (e.g. thyroid, renal
cell cancers), where 18F-FDG-PET is preferred (Table 2).
For prostate and mucinous digestive or gynaecological
cancer, tracers such as 18F-FCH have been recently
recommended.
The timing of response assessment with BS and
SPECT usually takes months, is non-evaluable in
patients with lytic or diﬀuse sclerotic (superscan) disease
and is confounded by the ﬂare phenomenon. Moreover,
these techniques only distinguish ‘progression/non-pro-
gression’ or ‘new lesion/no new lesions’ without the abil-
ity to identify early response/non-response [102] (Fig. 3).
MRI and PET/CT enable disease quantiﬁcation and cat-
egorisation of patients into partial/complete response,
progression or stable disease and thus objective identiﬁ-
cation of treatment beneﬁt. Whether limited to the axial
skeleton or targeting the whole body, MRI enables pre-
cise follow-up of lesion number, size and ‘mass’ on ana-
tomic T1 and on high b-value images and ADC
measurements are quantiﬁable [16,18,52,64]. The
EORTC or PERCIST PET response criteria [84,85] also
quantify metabolic and size response. Long term event/
progression/survival follow-up in osteophilic cancers
could justiﬁably consider use of BS+/–SPECT, but for
early response assessment, particularly when evaluatingnew drugs in clinical trials, or if radical changes in ther-
apy are considered, MRI and PET are recommended.
The need for contrast material or radiopharmaceutical,
radiation protection and patient tolerance, may be major
drivers in planning imaging [107]. In future, PET/MRI
hybrid scanners may well have a key role in evaluating
bony metastatic disease [108].5. Conclusion
The relative merits of MRI and PET for detecting
bone metastases and assessing their response to treat-
ment are summarised in Table 3. Standardisation of
data acquisition, contrast agent/radiopharmaceutical
choice, post-processing models and image quality are
key issues, especially in multicentre trials [109]. MRI
has some advantage over radionuclide studies because
of sensitivity and PET with cancer-oriented tracers
because of speciﬁcity. With nuclear medicine techniques,
distinguishing partial, complete response, stability or
progression is possible only with PET. 18F-FDG PET/
CT is currently the preferred cancer-oriented tracer,
except in prostate cancer where 11C or 18F-choline-
PET have better performance. Potential remains for
exploring speciﬁc agents by tumour type.
Much has been accomplished in the past few years in
terms of availability, reproducibility and aﬀordability to
translate these morphologic and functional techniques
2528 F.E. Lecouvet et al. / European Journal of Cancer 50 (2014) 2519–2531into clinical trials and daily oncology practice. Multicen-
tre validation and development of response criteria ded-
icated to bone metastases are embedded in several
ongoing EORTC studies.
Conﬂict of interest statement
None declared.
Acknowledgements
Frederic Lecouvet receives grant funding from
Fondation Saint Luc, Fondation contre la Cancer, and
FRS-FNRS Te´le´vie, Belgian non proﬁt organisations.
Jean-Noe¨l Talbot receives public funding from the
French Ministry of Health (PHRC) concerning PET
imaging of various cancers.
Nandita de Souza receives grant funding from Cancer
Research UK and National Institute of Health research,
UK.
Yan Liu is supported by the Fonds Cancer/FOCA
(Belgium).
The authors thank Nicolas Michoux, PhD, for his
precious advice in the early steps of this work.
References
[1] Eisenhauer EA, Therasse P, Bogaerts J, et al. New response
evaluation criteria in solid tumours: revised RECIST guideline
(version 1.1). Eur J Cancer 2009;45:228–47.
[2] Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to
evaluate the response to treatment in solid tumors. European
Organization for Research and Treatment of Cancer, National
Cancer Institute of the United States, National Cancer Institute
of Canada. J Natl Cancer Inst 2000;92:205–16.
[3] Saad F, Eastham JA, Smith MR. Biochemical markers of bone
turnover and clinical outcomes in men with prostate cancer.
Urologic Oncol 2012;30:369–78.
[4] O’Connor JP, Jackson A, Parker GJ, Jayson GC. DCE-MRI
biomarkers in the clinical evaluation of antiangiogenic and
vascular disrupting agents. Br J Cancer 2007;96:189–95.
[5] Charles-Edwards EM, de Souza NM. Diﬀusion-weighted mag-
netic resonance imaging and its application to cancer. Cancer
Imag 2006;6:135–43.
[6] Padhani AR, Miles KA. Multiparametric imaging of tumor
response to therapy. Radiology 2010;256:348–64.
[7] Harry VN, Semple SI, Parkin DE, Gilbert FJ. Use of new
imaging techniques to predict tumour response to therapy.
Lancet Oncol 2010;11:92–102.
[8] Heijmen L, Verstappen MC, Ter Voert EE, et al.
Tumour response prediction by diﬀusion-weighted MR imaging:
ready for clinical use? Crit Rev Oncol/Hematol 2012;83:
194–207.
[9] Biﬀar A, Sourbron S, Schmidt G, et al. Measurement of
perfusion and permeability from dynamic contrast-enhanced
MRI in normal and pathological vertebral bone marrow. Magn
Reson Med 2010;64:115–24.
[10] Biswal S, Resnick DL, Hoﬀman JM, Gambhir SS. Molecular
imaging: integration of molecular imaging into the musculoskel-
etal imaging practice. Radiology 2007;244:651–71.
[11] Daldrup-Link HE, Henning T, Link TM. MR imaging of
therapy-induced changes of bone marrow. Eur Radiol
2007;17:743–61.[12] Lecouvet FE, Larbi A, Pasoglou V, et al. MRI for response
assessment in metastatic bone disease. Eur Radiol
2013;23:1986–97.
[13] Messiou C, Cook G, de Souza NM. Imaging metastatic bone
disease from carcinoma of the prostate. Br J Cancer
2009;101:1225–32.
[14] Messiou C, Collins DJ, Morgan VA, Bianchini D, de Bono JS,
de Souza NM. Use of apparent diﬀusion coeﬃcient as a response
biomarker in bone: eﬀect of developing sclerosis on quantiﬁed
values. Skeletal Radiol 2014;43:205–8.
[15] Pearce T, Philip S, Brown J, Koh DM, Burn PR. Bone
metastases from prostate, breast and multiple myeloma: diﬀer-
ences in lesion conspicuity at short-tau inversion recovery and
diﬀusion-weighted MRI. Br J Radiol 2012;85:1102–6.
[16] Lecouvet FE, Simon M, Tombal B, Jamart J, Vande Berg BC,
Simoni P. Whole-body MRI (WB-MRI) versus axial skeleton
MRI (AS-MRI) to detect and measure bone metastases in
prostate cancer (PCa). Eur Radiol 2010;20:2973–82.
[17] Lecouvet FE, Geukens D, Stainier A, et al. Magnetic resonance
imaging of the axial skeleton for detecting bone metastases in
patients with high-risk prostate cancer: diagnostic and cost-
eﬀectiveness and comparison with current detection strategies. J
Clin Oncol 2007;25:3281–7.
[18] Messiou C, de Souza NM. Diﬀusion Weighted Magnetic
Resonance Imaging of metastatic bone disease: A biomarker
for treatment response monitoring. Cancer Biomarkers
2010;6:21–32.
[19] Bonekamp S, Corona-Villalobos CP, Kamel IR. Oncologic
applications of diﬀusion-weighted MRI in the body. J Magn
Reson Imag 2012;35:257–79.
[20] MessiouC,CollinsDJ,Giles S, deBono JS, BianchiniD, de Souza
NM. Assessing response in bone metastases in prostate cancer
with diﬀusion weighted MRI. Eur Radiol 2011;21:2169–77.
[21] Wu LM, Gu HY, Zheng J, et al. Diagnostic value of whole-body
magnetic resonance imaging for bone metastases: a systematic
review and meta-analysis. J Magn Reson Imaging
2011;34:128–35.
[22] Lecouvet FE, Vande Berg BC, Malghem J, Omoumi P, Simoni
P. Diﬀusion-weighted MR imaging: adjunct or alternative to T1-
weighted MR imaging for prostate carcinoma bone metastases?
Radiology 2009;252:624.
[23] Eiber M, Takei T, Souvatzoglou M, et al. Performance of whole-
body integrated 18F-FDG PET/MR in comparison to PET/CT
for evaluation of malignant bone lesions. J Nucl Med
2014;55(2):191–7.
[24] Linden HM, Stekhova SA, Link JM, et al. Quantitative
ﬂuoroestradiol positron emission tomography imaging predicts
response to endocrine treatment in breast cancer. J Clin Oncol
2006;24(18):2793–9.
[25] Gemignani ML, Patil S, Seshan VE, et al. Feasibility and
predictability of perioperative PET and estrogen receptor ligand
in patients with invasive breast cancer. J Nucl Med
2013;54(10):1697–702.
[26] van Kruchten M, Glaudemans AW, de Vries EF, et al. PET
imaging of estrogen receptors as a diagnostic tool for breast
cancer patients presenting with a clinical dilemma. J Nucl Med
2012;53(2):182–90.
[27] Larson SM, Morris M, Gunther I, et al. Tumor localization of
16beta-18F-ﬂuoro-5alpha-dihydrotestosterone versus 18F-FDG
in patients with progressive, metastatic prostate cancer. J Nucl
Med 2004;45(3):366–73.
[28] Afshar-Oromieh A, Zechmann CM, Malcher A, et al. Compar-
ison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-
choline-based PET/CT for the diagnosis of recurrent prostate
cancer. Eur J Nucl Med Mol Imag 2014;41(1):11–20.
[29] Ka¨hko¨nen E, Jambor I, Kemppainen J, et al. In vivo imaging of
prostate cancer using [68Ga]-labeled bombesin analog BAY86-
7548. Clin Cancer Res 2013;19(19):5434–43.
F.E. Lecouvet et al. / European Journal of Cancer 50 (2014) 2519–2531 2529[30] Ndlovu X, George R, Ellmann A, Warwick J. Should SPECT-
CT replace SPECT for the evaluation of equivocal bone scan
lesions in patients with underlying malignancies? Nucl Med
Commun 2010;31:659–65.
[31] Sharma P, Singh H, Kumar R, et al. Bone scintigraphy in breast
cancer: added value of hybrid SPECT-CT and its impact on
patient management. Nucl Med Commun 2012;33:139–47.
[32] Talbot JN, Paycha F, Balogova S. Diagnosis of bone metastasis:
recent comparative studies of imaging modalities. Q J Nucl Med
Mol Imag 2011;55:374–410.
[33] Zhang Y, Shi H, Cheng D, et al. Added value of SPECT/spiral
CT versus SPECT in diagnosing solitary spinal lesions in
patients with extraskeletal malignancies. Nucl Med Commun
2013;34:451–8.
[34] Yang HL, Liu T, Wang XM, Xu Y, Deng SM. Diagnosis of
bone metastases: a meta-analysis comparing 18FDG PET, CT,
MRI and bone scintigraphy. Eur Radiol 2011;21:2604–17.
[35] Helyar V, Mohan HK, Barwick T, et al. The added value of
multislice SPECT/CT in patients with equivocal bony metastasis
from carcinoma of the prostate. Eur J Nucl Med Mol Imag
2010;37:706–13.
[36] Chakraborty D, Bhattacharya A, Mete UK, Mittal BR. Com-
parison of 18F ﬂuoride PET/CT and 99mTc-MDP bone scan in
the detection of skeletal metastases in urinary bladder carci-
noma. Clin Nucl Med 2013;38:616–21.
[37] Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H,
Leibovitch I. The detection of bone metastases in patients with
high-risk prostate cancer: 99mTc-MDP Planar bone scintigra-
phy, single- and multi-ﬁeld-of-view SPECT, 18F-ﬂuoride PET,
and 18F-ﬂuoride PET/CT. J Nucl Med 2006;47:287–97.
[38] Hetzel M, Arslandemir C, Konig HH, et al. F-18 NaF PET for
detection of bone metastases in lung cancer: accuracy, cost-
eﬀectiveness, and impact on patient management. J Bone Miner
Res 2003;18:2206–14.
[39] Bourguet P, Blanc-Vincent MP, Boneu A, et al. Summary of the
Standards, Options and Recommendations for the use of
positron emission tomography with 2-[18F]ﬂuoro-2-deoxy-D-
glucose (FDP-PET scanning) in oncology (2002). Br J Cancer
2003;89(Suppl. 1):S84–91.
[40] Evangelista L, Panunzio A, Polverosi R, et al. Early bone
marrow metastasis detection: the additional value of FDG-PET/
CT vs. CT imaging. Biomed Pharmacother 2012;66:448–53.
[41] Banwait R, O’Regan K, Campigotto F, et al. The role of 18F-
FDG PET/CT imaging in Waldenstrom macroglobulinemia.
Am J Hematol 2011;86(7):567–72.
[42] Chan SC, Wang HM, Ng SH, et al. Utility of 18F-ﬂuoride PET/
CT and 18F-FDG PET/CT in the detection of bony metastases
in heightened-risk head and neck cancer patients. J Nucl Med
2012;53:1730–5.
[43] Damle NA, Bal C, Bandopadhyaya GP, et al. The role of 18F-
ﬂuoride PET-CT in the detection of bone metastases in patients
with breast, lung and prostate carcinoma: a comparison with
FDG PET/CT and 99mTc-MDP bone scan. Jpn J Radiol
2013;31:262–9.
[44] Kruger S, Buck AK, Mottaghy FM, et al. Detection of bone
metastases in patients with lung cancer: 99mTc-MDP planar bone
scintigraphy, 18F-ﬂuoride PET or 18F-FDG PET/CT. Eur J Nucl
Med Mol Imag 2009;36:1807–12.
[45] Langsteger W, Balogova S, Huchet V, et al. Fluorocholine (18F)
and sodium ﬂuoride (18F) PET/CT in the detection of prostate
cancer: prospective comparison of diagnostic performance
determined by masked reading. Q J Nucl Med Mol Imag
2011;55:448–57.
[46] Balogova S, Talbot JN, Nataf V, et al. 18F-ﬂuorodihydroxyphe-
nylalanine vs other radiopharmaceuticals for imaging neuroen-
docrine tumours according to their type. Eur J Nucl Med Mol
Imag 2013;40:943–66.[47] Costelloe CM, Kundra V, Ma J, et al. Fast Dixon whole-body
MRI for detecting distant cancer metastasis: a preliminary
clinical study. J Magn Reson Imaging 2012;35:399–408.
[48] Ghanem N, Altehoefer C, Hogerle S, et al. Comparative
diagnostic value and therapeutic relevance of magnetic reso-
nance imaging and bone marrow scintigraphy in patients with
metastatic solid tumors of the axial skeleton. Eur J Radiol
2002;43:256–61.
[49] Brown AL, Middleton G, MacVicar AD, Husband JE. T1-
weighted magnetic resonance imaging in breast cancer vertebral
metastases: changes on treatment and correlation with response
to therapy. Clin Radiol 1998;53:493–501.
[50] Saip P, Tenekeci N, Aydiner A, et al. Response evaluation of
bone metastases in breast cancer: value of magnetic resonance
imaging. Cancer Invest 1999;17:575–80.
[51] Ciray I, Lindman H, Astrom KG, Bergh J, Ahlstrom KH. Early
response of breast cancer bone metastases to chemotherapy
evaluated with MR imaging. Acta Radiol 2001;42:198–206.
[52] Tombal B, Rezazadeh A, Therasse P, Van Cangh PJ, Vande
Berg B, Lecouvet FE. Magnetic resonance imaging of the axial
skeleton enables objective measurement of tumor response on
prostate cancer bone metastases. Prostate 2005;65:178–87.
[53] Graham TJ, Box G, Tunariu N, Crespo M, Spinks TJ, Miranda
S, et al. Preclinical evaluation of imaging biomarkers for
prostate cancer bone metastasis and response to cabozantinib.
J Natl Cancer Inst 2014;106:dju033.
[54] Lee KC, Sud S, Meyer CR, et al. An imaging biomarker of early
treatment response in prostate cancer that has metastasized to
the bone. Cancer Res 2007;67:3524–8.
[55] Rozel S, Galban CJ, Nicolay K, et al. Synergy between anti-
CCL2 and docetaxel as determined by DW-MRI in a metastatic
bone cancer model. J Cell Biochem 2009;107:58–64.
[56] Bauerle T, Bartling S, Berger M, et al. Imaging anti-angiogenic
treatment response with DCE-VCT, DCE-MRI and DWI in an
animal model of breast cancer bone metastasis. Eur J Radiol
2010;73:280–7.
[57] Reischauer C, Froehlich JM, Koh DM, et al. Bone metastases
from prostate cancer: assessing treatment response by using
diﬀusion-weighted imaging and functional diﬀusion maps –
initial observations. Radiology 2010;257:523–31.
[58] Byun BH, Kong CB, Lim I, Choi CW, Song WS, Cho WH, et al.
Combination of 18F-FDG PET/CT and diﬀusion-weighted MR
imaging as a predictor of histologic response to neoadjuvant
chemotherapy: preliminary results in osteosarcoma. J Nucl Med
2013 Jul;54(7):1053–9.
[59] Blackledge MD, Collins DJ, Tunariu N, Orton MR, Padhani
AR, Leach MO, et al. Assessment of treatment response by total
tumor volume and global apparent diﬀusion coeﬃcient using
diﬀusion-weighted MRI in patients with metastatic bone disease:
a feasibility study. PLoS ONE 2014;9:e91779.
[60] Montemurro F, Russo F, Martincich L, et al. Dynamic contrast
enhanced magnetic resonance imaging in monitoring bone
metastases in breast cancer patients receiving bisphosphonates
and endocrine therapy. Acta Radiol 2004;45:71–4.
[61] Budde MD, Gold E, Jordan EK, Frank JA. Diﬀerential
microstructure and physiology of brain and bone metastases in
a rat breast cancer model by diﬀusion and dynamic contrast
enhanced MRI. Clin Exp Metastasis 2012;29:51–62.
[62] Vassiliou V, Andreopoulos D. Assessment of therapeutic
response in patients with metastatic skeletal disease: suggested
modiﬁcations for the MDA response classiﬁcation criteria. Br J
Cancer 2010;103:925–6 [author reply 7].
[63] Lee KC, Bradley DA, Hussain M, et al. A feasibility study
evaluating the functional diﬀusion map as a predictive imaging
biomarker for detection of treatment response in a patient with
metastatic prostate cancer to the bone. Neoplasia
2007;9:1003–11.
2530 F.E. Lecouvet et al. / European Journal of Cancer 50 (2014) 2519–2531[64] Padhani AR, Makris A, Gall P, Collins DJ, Tunariu N, DeBono
JS. Therapy monitoring of skeletal metastases with whole-body
diﬀusion MRI. J Magn Reson Imaging 2014;39(5):1049–78.
[65] Coleman R, Gnant M, Morgan G, Clezardin P. Eﬀects of bone-
targeted agents on cancer progression and mortality. J Natl
Cancer Inst 2012;104:1059–67.
[66] Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid
versus placebo in the treatment of skeletal metastases in patients
with lung cancer and other solid tumors: a phase III, double-
blind, randomized trial – the Zoledronic Acid Lung Cancer and
Other Solid Tumors Study Group. J Clin Oncol 2003;21:3150–7.
[67] Mitsui Y, Shiina H, Yamamoto Y, et al. Prediction of survival
beneﬁt using an automated bone scan index in patients with
castration-resistant prostate cancer. BJU Int 2012;110:E628–34.
[68] Brown MS, Chu GH, Kim HJ, et al. Computer-aided quanti-
tative bone scan assessment of prostate cancer treatment
response. Nucl Med Commun 2012;33:384–94.
[69] Coleman RE, Mashiter G, Whitaker KB, Moss DW, Rubens
RD, Fogelman I. Bone scan ﬂare predicts successful systemic
therapy for bone metastases. J Nucl Med 1988;29:1354–9.
[70] Coleman RE, Mashiter G, Fogelman I, Whitaker KD, Caleﬃ
M, Moss DW, et al. Osteocalcin: a potential marker of
metastatic bone disease and response to treatment. Eur J Cancer
Clin Oncol 1988;24:1211–7.
[71] Scher HI, Yagoda A. Bone metastases: pathogenesis, treatment,
and rationale for use of resorption inhibitors. Am J Med
1987;82:6–28.
[72] Coleman RE, Whitaker KB, Moss DW, Mashiter G, Fogelman
I, Rubens RD. Biochemical prediction of response of bone
metastases to treatment. Br J Cancer 1988;58:205–10.
[73] Pollen JJ, Witztum KF, Ashburn WL. The ﬂare phenomenon on
radionuclide bone scan in metastatic prostate cancer. AJR Am J
Roentgenol 1984;142:773–6.
[74] Ryan CJ, Shah S, Efstathiou E, et al. Phase II study of
abiraterone acetate in chemotherapy-naive metastatic castration-
resistant prostate cancer displaying bone ﬂare discordant with
serologic response. Clin Cancer Res 2011;17:4854–61.
[75] DeMeo JH, Balseiro J, Cole TJ. Etidronate sodium therapy – a
cause of poor skeletal radiopharmaceutical uptake. Semin Nucl
Med 1991;21:332–4.
[76] Roudier MP, Vesselle H, True LD, et al. Bone histology at
autopsy and matched bone scintigraphy ﬁndings in patients with
hormone refractory prostate cancer: the eﬀect of bisphosphonate
therapy on bone scintigraphy results. Clin Exp Metastasis
2003;20:171–80.
[77] Cook Jr G, Parker C, Chua S, et al. 18F-ﬂuoride PET: changes in
uptake as a method to assess response in bone metastases
from castrate-resistant prostate cancer patients treated with
223Ra-chloride (Alpharadin). EJNMMI Res 2011:1–4.
[78] Wade AA, Scott JA, Kuter I, Fischman AJ. Flare response in
18F-ﬂuoride ion PET bone scanning. AJR Am J Roentgenol
2006;186:1783–6.
[79] Installe J, Nzeusseu A, Bol A, Depresseux G, Devogelaer JP,
Lonneux M. (18)F-ﬂuoride PET for monitoring therapeutic
response in Paget’s disease of bone. J Nucl Med 2005;46:1650–8.
[80] Balogova S, Huchet V, Egrot C, et al. Eﬀect of erythropoietin on
bone marrow uptake of 18F-ﬂuorocholine in prostate cancer:
comparison with 18F-ﬂuoride uptake. Clin Nucl Med
2013;38:200–2.
[81] Avery R, Kuo PH. 18F sodium ﬂuoride PET/CT detects osseous
metastases from breast cancer missed on FDG PET/CT with
marrow rebound. Clin Nucl Med 2013;38:746–8.
[82] Cachin F, Prince HM, Hogg A, Ware RE, Hicks RJ. Powerful
prognostic stratiﬁcation by [18F]ﬂuorodeoxyglucose positron
emission tomography in patients with metastatic breast cancer
treated with high-dose chemotherapy. J Clin Oncol
2006;24:3026–31.[83] Staﬀord SE, Gralow JR, Schubert EK, et al. Use of serial FDG
PET to measure the response of bone-dominant breast cancer to
therapy. Acad Radiol 2002;9:913–21.
[84] Young H, Baum R, Cremerius U, et al. Measurement of clinical
and subclinical tumour response using [18F]-ﬂuorodeoxyglucose
and positron emission tomography: review and 1999 EORTC
recommendations. European Organization for Research and
Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer
1999;35:1773–82.
[85] Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to
PERCIST: Evolving considerations for PET response criteria in
solid tumors. J Nucl Med 2009;50(Suppl. 1):122S–50S.
[86] Thacker CA, Weiss GJ, Tibes R, et al. 18-FDG PET/CT
assessment of basal cell carcinoma with vismodegib. Cancer Med
2012;1(2):230–6.
[87] Skougaard K, Nielsen D, Jensen BV, Hendel HW. Comparison
of EORTC criteria and PERCIST for PET/CT response
evaluation of patients with metastatic colorectal cancer treated
with irinotecan and cetuximab. J Nucl Med 2013;54(7):
1026–31.
[88] Katayama T, Kubota K, Machida Y, Toriihara A, Shibuya H.
Evaluation of sequential FDG-PET/CT for monitoring bone
metastasis of breast cancer during therapy: correlation between
morphological and metabolic changes with tumor markers. Ann
Nucl Med 2012;26:426–35.
[89] Huyge V, Garcia C, Alexiou J, et al. Heterogeneity of metabolic
response to systemic therapy in metastatic breast cancer patients.
Clinl Oncol(R Coll Radiol) 2010;22(10):818–27.
[90] Mortimer JE, Dehdashti F, Siegel BA, Trinkaus K, Katzenel-
lenbogen JA, Welch MJ. Metabolic ﬂare: indicator of hormone
responsiveness in advanced breast cancer. J Clin Oncol
2001;19:2797–803.
[91] Mortazavi-Jehanno N, Giraudet AL, Champion L, et al.
Assessment of response to endocrine therapy using FDG PET/
CT in metastatic breast cancer: a pilot study. Eur J Nucl Med
Mol Imag 2012;39:450–60.
[92] Balogova S, Ben Zakoun J, Michaud L, et al. FCH PET/CT and
MRI of the spine for monitoring patients with castration-
resistant prostate cancer metastatic to bone – a pilot study.
Nuklearmedizin 2013;52(6):A124–5.
[93] Gabriel M, Oberauer A, Dobrozemsky G, et al. 68Ga-DOTA-
Tyr3-octreotide PET for assessing response to somatostatin-
receptor-mediated radionuclide therapy. J Nucl Med
2009;50:1427–34.
[94] Gordon I, Peters AM, Gutman A, Morony S, Dicks-Mireaux C,
Pritchard J. Skeletal assessment in neuroblastoma – the pitfalls
of iodine-123-MIBG scans. J Nucl Med 1990;31:129–34.
[95] Troncone L, Ruﬁni V, Montemaggi P, Danza FM, Lasorella A,
Mastrangelo R. The diagnostic and therapeutic utility of
radioiodinated metaiodobenzylguanidine (MIBG). 5 years of
experience. Eur J Nucl Med 1990;16:325–35.
[96] Pﬂuger T, Schmied C, Porn U, et al. Integrated imaging using
MRI and 123I metaiodobenzylguanidine scintigraphy to
improve sensitivity and speciﬁcity in the diagnosis of pediatric
neuroblastoma. AJR Am J Roentgenol 2003;181:1115–24.
[97] Leboulleux S, Dromain C, Vataire AL, et al. Prediction and
diagnosis of bone metastases in well-diﬀerentiated gastro-entero-
pancreatic endocrine cancer: a prospective comparison of whole
body magnetic resonance imaging and somatostatin receptor
scintigraphy. J Clin Endocrinol Metabol 2008;93:3021–8.
[98] Lebtahi R, Cadiot G, Delahaye N, et al. Detection of bone
metastases in patients with endocrine gastroenteropancreatic
tumors: bone scintigraphy compared with somatostatin receptor
scintigraphy. J Nucl Med 1999;40:1602–8.
[99] Zuetenhorst JM, Hoefnageli CA, Boot H, Valdes Olmos RA,
Taal BG. Evaluation of (111)In-pentetreotide, (131)I-MIBG and
bone scintigraphy in the detection and clinical management of
F.E. Lecouvet et al. / European Journal of Cancer 50 (2014) 2519–2531 2531bone metastases in carcinoid disease. Nucl Med Commun
2002;23:735–41.
[100] Timmers HJ, Chen CC, Carrasquillo JA, et al. Staging and
functional characterization of pheochromocytoma and paragan-
glioma by 18F-ﬂuorodeoxyglucose (18F-FDG) positron emission
tomography. J Natl Cancer Inst 2012;104:700–8.
[101] Kenny LM, Coombes RC, Oulie I, et al. Phase I trial of
the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand
18F-AH111585 in breast cancer patients. J Nucl Med 2008;49(6):
879–86.
[102] Scher HI, Halabi S, Tannock I, et al. Design and end points of
clinical trials for patients with progressive prostate cancer and
castrate levels of testosterone: recommendations of the Prostate
Cancer Clinical Trials Working Group. J Clin Oncol
2008;26:1148–59.
[103] Fox JJ, Morris MJ, Larson SM, Scho¨der H, Scher HI.
Developing imaging strategies for castration resistant prostate
cancer. Acta Oncol 2011;50(Suppl. 1):39–48.
[104] Mulders PF, Schalken JA. Measuring therapeutic eﬃcacy in the
changing paradigm of castrate-resistant prostate cancer. Prostate
Cancer Prostatic Dis 2009;12:241–6.[105] Fitzpatrick JM, Bellmunt J, Fizazi K, et al. Optimal manage-
ment of metastatic castration-resistant prostate cancer: high-
lights from a European Expert Consensus Panel. Eur J Cancer
2014;50:1617–27.
[106] Kwee SA, De Grado TR, Talbot JN, et al. Cancer imaging with
ﬂuorine-18-labeled choline derivatives. Semin Nucl Med
2007;37(6):420–8.
[107] Linton KD, Catto JW. Whole-body magnetic resonance imaging
and prostate cancer metastases: a new gold standard of
detection, but does it help us and at what cost? Eur Urol
2012;62:76–7.
[108] Gaeta CM, Vercher-Conejero JL, Sher AC, Kohan A, Rubbert
C, Avril N. Recurrent and metastatic breast cancer PET, PET/
CT, PET/MRI: FDG and new biomarkers. Q J Nucl Med Mol
Imag 2013;57:352–66.
[109] Ashton E, Riek J. Advanced MR techniques in multicenter
clinical trials. J Magn Reson Imaging 2013;37:761–9.
